Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study

Danni Li, Jeffrey R. Misialek, Eric Boerwinkle, Rebecca F. Gottesman, A. Richey Sharrett, Thomas H. Mosley, Josef Coresh, Lisa M. Wruck, David S Knopman, Alvaro Alonso

Research output: Contribution to journalArticle

11 Scopus citations


Introduction The objective of this study was to investigate whether 10 phospholipids/metabolites previously identified as prospectively predictive of mild cognitive impairment (MCI) or dementia in whites would also be predictive in a mostly African-American cohort. Methods We repeatedly measured 188 phospholipids/metabolites in plasma samples of 221 participants of the Atherosclerosis Risk in Communities study, 97% African American, who were followed between 2004–2006 and 2011–2013. Results After a mean follow-up of 7.3 years, 77 were classified as having MCI and 18 as having dementia. Our study failed to replicate previous findings in this mostly African American cohort, in that the 10 phospholipids/metabolites only achieved a C statistic/AUC of 0.609 in predicting development of MCI or dementia (compared to 0.96) and 0.607 in distinguishing normal from MCI or dementia at the follow-up visit. Conclusion A panel of 10 phospholipids/metabolites previously associated with incident dementia was not predictive of MCI or dementia in an independent cohort.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
StatePublished - 2017



  • AD
  • Alzheimer's disease
  • ARIC
  • Dementia
  • MCI
  • Metabolites
  • Metabolomics
  • Mild cognitive impairment
  • Phospholipids
  • Plasma

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this